Status:
RECRUITING
Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Lead Sponsor:
NewAmsterdam Pharma
Conditions:
Dyslipidemias
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) t...
Eligibility Criteria
Inclusion
- Lp(a): \>=50 mg/dL (\>=125 nmol/L) for cohort 1 (FILLED) and Lp(a) \>= 20 mg/dL (\>= 50 nmol/L) to \<50 mg/dL (\< 125 nmol/L) for cohort 2
- LDL-C \>70 mg/dL
- TG \< 400mg/dL (\<4.52 mmol/L)
Exclusion
- HbA1c\>=10 or FPG \>=270 mg/dL
- CV events within 3 months of screen
Key Trial Info
Start Date :
December 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT06496243
Start Date
December 2 2024
End Date
February 1 2026
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPenn
Philadelphia, Pennsylvania, United States, 19104